Breast cancer is an escalating public health concern in Sub-Saharan Africa (SSA), where mortality rates remain disproportionately high despite lower incidence compared to Western countries. The combination of late-stage diagnoses, limited healthcare infrastructure, and socioeconomic inequalities severely compromises patient outcomes.

We conducted a systematic review and meta-analysis of 85 studies encompassing 33,053 patients across SSA to characterize breast cancer profiles, focusing on age at diagnosis, cancer stage, molecular subtypes, and survival outcomes.

The mean age at diagnosis was 48.7 years, notably younger than in high-income regions. Half of the patients were diagnosed at stage III, and only 4% at stage I. Luminal A was the most prevalent molecular subtype (30%), followed closely by triple-negative breast cancer (29%), known for its aggressive course and limited treatment options. Survival analysis revealed a pooled 5-year survival rate of 44%, with substantial regional disparities: survival was poorest in West Africa and comparatively better in East Africa and South Africa.

Our findings expose the critical need for regionally tailored interventions to improve early detection, expand access to comprehensive treatment, and address underlying social determinants of health. This study delivers essential epidemiological benchmarks that should inform targeted strategies for reducing the breast cancer burden and improving survival across Sub-Saharan Africa.